Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Cost of Revenue: 2020-2025

Historic Cost of Revenue for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to $64,000.

  • Silence Therapeutics' Cost of Revenue fell 98.24% to $64,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 80.42%. This contributed to the annual value of $11.8 million for FY2024, which is 8.21% down from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Cost of Revenue is $64,000, which was down 24.71% from $85,000 recorded in Q2 2025.
  • Silence Therapeutics' 5-year Cost of Revenue high stood at $2.1 billion for Q1 2021, and its period low was $54,000 during Q1 2025.
  • Over the past 3 years, Silence Therapeutics' median Cost of Revenue value was $2.0 million (recorded in 2024), while the average stood at $2.3 million.
  • Over the last 5 years, Silence Therapeutics' Cost of Revenue had its largest YoY gain of 100.09% in 2021, and its largest YoY loss of 99.91% in 2021.
  • Silence Therapeutics' Cost of Revenue (Quarterly) stood at $2.8 million in 2021, then skyrocketed by 64.44% to $4.5 million in 2022, then tumbled by 63.09% to $1.7 million in 2023, then rose by 21.99% to $2.0 million in 2024, then slumped by 98.24% to $64,000 in 2025.
  • Its last three reported values are $64,000 in Q3 2025, $85,000 for Q2 2025, and $54,000 during Q1 2025.